We are a strategic advisory and equity investment firm with decades of experience in preclinical drug development. Our extensive knowledge base covers all aspects related to advancing early stage drug candidates toward human clinical testing such as drug manufacturing, drug product formulation, analytical/bioanalytical methods development and animal safety, toxicology, pharmacology, immunology and pharmacokinetic testing. We leverage our expertise by combining it with a wide range of preclinical services offered by our CRO affiliate, Calvert Laboratories in addition to trusted subcontractors to design and execute customized drug development partnership programs with preclinical stage biopharmaceutical companies.
| Website | http://www.calvert-research.com |
| Revenue | $5.2 million |
| Employees | 1 (0 on RocketReach) |
| Founded | 2008 |
| Phone | +1 919-459-8665 |
| Technologies |
JavaScript
,
PHP
,
Google Analytics
+3 more
(view full list)
|
| Industry | Pharmaceuticals, Finance General, Financial Services, Finance, Research |
| Keywords | Preclinical Drug Development, Drug Development Consulting, Drug Discovery Consulting, Biopharmaceutical Consulting, Strategic Advisory Services, Biotech Consulting, Pharmaceutical Investment, Pharmaceutical Consulting, Clinical Trial Support, Investment Advisory Services, Strategic Partnerships, Capital Advisory, Venture Capital, Research And Development |
| Competitors | IIT Research Institute (IITRI), Resolian, Melior Discovery, PRESCOS LLC, Daedalus Biotech Advisors (view competitors) |
| SIC | SIC Code 87 Companies, SIC Code 62 Companies |
| NAICS | NAICS Code 52311 Companies, NAICS Code 523 Companies, NAICS Code 523110 Companies, NAICS Code 5231 Companies, NAICS Code 52 Companies |
Looking for a particular Calvert Research employee's phone or email?
The Calvert Research annual revenue was $5.2 million in 2026.
The NAICS codes for Calvert Research are [52311, 523, 523110, 5231, 52].
The SIC codes for Calvert Research are [87, 62].